Kalaris Therapeutics, Inc. (KLRS): EPS (Diluted)
-$2.85
Year ended 2025-12-31
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$2.85 | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$51.77 | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$42.09 | n/c | 2025-03-07, From 2023-01-01 |
| 2022-12-31 | -$2.20 | n/m | 2024-03-15, From 2022-01-01 |
| 2021-12-31 | -$2.74 | n/a | 2023-02-15, From 2021-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | -$2.85 | n/m |
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | -$2.00 | n/m |
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | -$0.72 | n/m |
| Humacyte, Inc. (HUMA) | 2025-12-31 | -$0.26 | n/m |
| Zura Bio Ltd (ZURA) | 2025-12-31 | -$1.06 | n/m |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | -$23.04 | n/m |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | -$3.43 | n/m |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$0.28 | n/m |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | -$0.30 | n/m |
Compare KLRS, ABOS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗